Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations


Haznedaroglu I. C.

EXPERT OPINION ON PHARMACOTHERAPY, vol.14, no.15, pp.2005-2010, 2013 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Editorial Material
  • Volume: 14 Issue: 15
  • Publication Date: 2013
  • Doi Number: 10.1517/14656566.2013.833185
  • Title of Journal : EXPERT OPINION ON PHARMACOTHERAPY
  • Page Numbers: pp.2005-2010

Abstract

Introduction: The aim of this paper is to indicate optimal tyrosine kinase inhibitor (TKI) administration practices based on European LeukemiaNet (ELN) 2013 recommendations for chronic myeloid leukemia (CML). Likewise, current concerns of undertreatment and overtreatment with TKIs during the long-term clinical course of CML will be outlined.